Abdul-Ghani, Muhammad et al. ‘Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?’ Diabetes Care 40.7 (2017): 813–820. Web.
Adamsson Eryd, S. et al. ‘Risk of Future Microvascular and Macrovascular Disease in People with Type 1 Diabetes of Very Long Duration: A National Study with 10-Year Follow-Up’. Diabetic Medicine 34.3 (2017): 411–418. Web.
Andersson, Daniel P et al. ‘Association between Treatment for Erectile Dysfunction and Death or Cardiovascular Outcomes after Myocardial Infarction’. Heart (2017): n. pag. Web.
‘Assessing the Relationship between Admission Glucose Levels, Subsequent Length of Hospital Stay, Readmission and Mortality.’ Prime n. pag. Web. <https://wwww.unboundmedicine.com/medline/citation/22586788/Assessing_the_relationship_between_admission_glucose_levels_subsequent_length_of_hospital_stay_readmission_and_mortality_>.
Atkinson, Mark A, George S Eisenbarth, and Aaron W Michels. ‘Type 1 Diabetes’. The Lancet 383.9911 (2014): 69–82. Web.
Azmi, Shazli et al. ‘Small-Fibre Neuropathy in Men with Type 1 Diabetes and Erectile Dysfunction: A Cross-Sectional Study’. Diabetologia (2017): n. pag. Web.
Bangalore, S. et al. ‘Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials’. Circulation 123.24 (2011): 2799–2810. Web.
Barzilay, J. I. et al. ‘Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Outcomes in People Treated for Hypertension: The ALLHAT Diabetes Extension Study’. Circulation: Cardiovascular Quality and Outcomes 5.2 (2012): 153–162. Web.
Bianchi, Cristina, Roberto Miccoli, and Stefano Del Prato. ‘Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction?’ Current Diabetes Reports 13.3 (2013): 403–410. Web.
---. ‘Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction?’ Current Diabetes Reports 13.3 (2013): 403–410. Web.
Black, J. A. et al. ‘Change in Cardiovascular Risk Factors Following Early Diagnosis of Type 2 Diabetes: A Cohort Analysis of a Cluster-Randomised Trial’. British Journal of General Practice 64.621 (2014): e208–e216. Web.
Boulton, Andrew JM et al. ‘International Collaborative Research on Charcot’s Disease - 2009’. The Lancet 373.9658 (2009): 105–106. Web.
Boussageon, R. et al. ‘Effect of Intensive Glucose Lowering Treatment on All Cause Mortality, Cardiovascular Death, and Microvascular Events in Type 2 Diabetes: Meta-Analysis of Randomised Controlled Trials’. BMJ 343.jul26 1 (2011): d4169–d4169. Web.
Braffett, Barbara H., Hunter Wessells, and Aruna V. Sarma. ‘Urogenital Autonomic Dysfunction in Diabetes’. Current Diabetes Reports 16.12 (2016): n. pag. Web.
Çakici, N. et al. ‘Systematic Review of Treatments for Diabetic Peripheral Neuropathy’. Diabetic Medicine 33.11 (2016): 1466–1476. Web.
---. ‘Systematic Review of Treatments for Diabetic Peripheral Neuropathy’. Diabetic Medicine 33.11 (2016): 1466–1476. Web.
‘Cardiovascular Outcome Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes - ClinicalKey’. N.p., n.d. Web. <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0140673614607947>.
Cefalu, William T. et al. ‘Getting to the "Heart” of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory”’. Diabetes Care 39.5 (2016): 664–667. Web.
Chatterjee, Sudesna, Kamlesh Khunti, and Melanie J Davies. ‘Type 2 Diabetes’. The Lancet (2017): n. pag. Web.
Cheung, Ning, Paul Mitchell, and Tien Yin Wong. ‘Diabetic Retinopathy’. The Lancet 376.9735 (2010): 124–136. Web.
Chloe L. Edridge. ‘Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and Meta-Analysis of Population Based Studies’. PLoS ONE 10.6 (2015): n. pag. Web. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465495/>.
Clokie, M. et al. ‘New Horizons in the Understanding of the Causes and Management of Diabetic Foot Disease: Report from the 2017 Diabetes UK Annual Professional Conference Symposium’. Diabetic Medicine 34.3 (2017): 305–315. Web.
Dahlöf, Björn et al. ‘Prevention of Cardiovascular Events with an Antihypertensive Regimen of Amlodipine Adding Perindopril as Required versus Atenolol Adding Bendroflumethiazide as Required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A Multicentre Randomised Controlled Trial’. The Lancet 366.9489 (2005): 895–906. Web.
Dana Dabelea. ‘Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood’. JAMA 317.8 825–835. Web. <http://jamanetwork.com/journals/jama/fullarticle/2606400>.
Denig, P. et al. ‘Effects of a Patient Oriented Decision Aid for Prioritising Treatment Goals in Diabetes: Pragmatic Randomised Controlled Trial’. BMJ 349.sep25 6 (2014): g5651–g5651. Web.
Dhatariya, K. et al. ‘NHS Diabetes Guideline for the Perioperative Management of the Adult Patient with Diabetes’. Diabetic Medicine 29.4 (2012): 420–433. Web.
Dhatariya, Ketan K., and Priyathama Vellanki. ‘Treatment of Diabetic Ketoacidosis (DKA)/Hyperglycemic Hyperosmolar State (HHS): Novel Advances in the Management of Hyperglycemic Crises (UK Versus USA)’. Current Diabetes Reports 17.5 (2017): n. pag. Web.
‘Diabetes Mellitus, Fasting Blood Glucose Concentration, and Risk of Vascular Disease: A Collaborative Meta-Analysis of 102 Prospective Studies’. The Lancet 375.9733 (2010): 2215–2222. Web.
‘Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death’. New England Journal of Medicine 364.9 (2011): 829–841. Web.
‘Diabetes Mellitus Type 2: A Driving Force for Urological Complications - ClinicalKey’. N.p., n.d. Web. <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321>.
‘---’. N.p., n.d. Web. <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1043276016000321>.
‘Diabetic Foot Problems: Prevention and Management | Guidance and Guidelines | NICE’. n. pag. Web. <https://www.nice.org.uk/guidance/ng19>.
Duckworth, William et al. ‘Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes’. New England Journal of Medicine 360.2 (2009): 129–139. Web.
Dwamena, Francesca et al. ‘Interventions for Providers to Promote a Patient-Centred Approach in Clinical Consultations’. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 1996. Web. <http://doi.wiley.com/10.1002/14651858.CD003267.pub2>.
‘Effect of Intensive Blood-Glucose Control with Metformin on Complications in Overweight Patients with Type 2 Diabetes (UKPDS 34)’. The Lancet 352.9131 (1998): 854–865. Web.
‘Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus’. New England Journal of Medicine 362.17 (2010): 1563–1574. Web.
‘Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus’. Archives of Internal Medicine 165.12 (2005): n. pag. Web.
‘Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus’. New England Journal of Medicine 362.17 (2010): 1575–1585. Web.
‘---’. New England Journal of Medicine 362.17 (2010): 1575–1585. Web.
‘Effects of Intensive Glucose Lowering in Type 2 Diabetes’. New England Journal of Medicine 358.24 (2008): 2545–2559. Web.
‘Effects of Reducing Blood Pressure on Renal Outcomes in Patients with Type 2 Diabetes: Focus on SGLT2 Inhibitors and EMPA-REG OUTCOME - ClinicalKey’. n. pag. Web. <https://www.clinicalkey.com/#!/content/journal/1-s2.0-S1262363617300022>.
Ele Ferrannini. ‘Impact of Glucose-Lowering Drugs on Cardiovascular Disease in Type 2 Diabetes’. European Heart Journal 36.34 (2015): 2288–2296. Web. <http://eurheartj.oxfordjournals.org/content/36/34/2288>.
Elliott, William J, and Peter M Meyer. ‘Incident Diabetes in Clinical Trials of Antihypertensive Drugs: A Network Meta-Analysis’. The Lancet 369.9557 (2007): 201–207. Web.
Ferrannini, Ele, and William C Cushman. ‘Diabetes and Hypertension: The Bad Companions’. The Lancet 380.9841 (2012): 601–610. Web.
Filippatos, Theodosios et al. ‘Pathophysiology of Diabetic Dyslipidaemia’. Current Vascular Pharmacology 15.999 (2017): 1–1. Print.
Fisher, L., J. S. Gonzalez, and W. H. Polonsky. ‘The Confusing Tale of Depression and Distress in Patients with Diabetes: A Call for Greater Clarity and Precision’. Diabetic Medicine 31.7 (2014): 764–772. Web.
Foresta, C. et al. ‘The Great Opportunity of the Andrological Patient: Cardiovascular and Metabolic Risk Assessment and Prevention’. Andrology (2017): n. pag. Web.
Fox, Caroline S. et al. ‘Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association’. Diabetes Care 38.9 (2015): 1777–1803. Web.
‘Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes’. New England Journal of Medicine 376.16 (2017): 1507–1516. Web.
Gæde, Peter, Henrik Lund-Andersen, et al. ‘Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes’. New England Journal of Medicine 358.6 (2008): 580–591. Web.
Gæde, Peter, Jens Oellgaard, et al. ‘Years of Life Gained by Multifactorial Intervention in Patients with Type 2 Diabetes Mellitus and Microalbuminuria: 21 Years Follow-up on the Steno-2 Randomised Trial’. Diabetologia 59.11 (2016): 2298–2307. Web.
Game, Frances. ‘Classification of Diabetic Foot Ulcers’. Diabetes/Metabolism Research and Reviews 32 (2016): 186–194. Web.
Giorgino, Francesco, Philip D. Home, and Jaakko Tuomilehto. ‘Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?’ Diabetes Care 39.Supplement 2 (2016): S187–S195. Web.
Giovanni Corona. ‘Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors’. PLoS ONE 11.10 (2016): n. pag. Web. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051725/>.
Hayward, Rodney A. et al. ‘Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes’. New England Journal of Medicine 372.23 (2015): 2197–2206. Web.
---. ‘Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes’. New England Journal of Medicine 372.23 (2015): 2197–2206. Web.
Holman, Rury R., Sanjoy K. Paul, et al. ‘10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes’. New England Journal of Medicine 359.15 (2008): 1577–1589. Web.
Holman, Rury R., M. Angelyn Bethel, et al. ‘Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes’. New England Journal of Medicine 377.13 (2017): 1228–1239. Web.
Holt, R. I. G. ‘Understanding of the Causes and Management of Diabetic Foot Disease’. Diabetic Medicine 34.3 (2017): 303–304. Web.
Holt, Richard I. G., Clive Cockram, et al. Textbook of Diabetes. 5th ed. Somerset: John Wiley & Sons, Incorporated, 2016. Web. <http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>.
Holt, Richard I. G. Textbook of Diabetes. 4th ed. Chichester: Wiley-Blackwell, 2010. Web. <http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>.
Holt, Richard I. G., Clive S. Cockram, et al., eds. Textbook of Diabetes. Fifth edition. Chichester, West Sussex, UK: Wiley Blackwell, 2017. Web. <http://ezproxy.lib.le.ac.uk/login?url=http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=4769056>.
Hotaling, James M. et al. ‘Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes’. Diabetes Care 39.9 (2016): 1587–1593. Web.
---. ‘Cardiovascular Autonomic Neuropathy, Sexual Dysfunction, and Urinary Incontinence in Women With Type 1 Diabetes’. Diabetes Care 39.9 (2016): 1587–1593. Web.
‘Hypertension: Clinical Management of Primary Hypertension in Adults | NICE Guideline 127. August 2011’. N.p., n.d. Web. <http://www.nice.org.uk/guidance/cg127>.
Ian Blumer, MD, FRCPC1, 2, Maureen Clement, MD, CCFP3, ,. ‘Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges’. Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges n. pag. Web. <http://www.sciencedirect.com.ezproxy4.lib.le.ac.uk/science/article/pii/S0149291816307792>.
‘Integration of Recent Evidence into Management of Patients with Atherosclerotic Cardiovascular Disease and Type 2 Diabetes - ClinicalKey’. n. pag. Web. <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858717300335>.
‘Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes’. New England Journal of Medicine 358.24 (2008): 2560–2572. Web.
‘Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes’. New England Journal of Medicine 353.25 (2005): 2643–2653. Web.
‘Intensive Systolic Blood Pressure Control and Incident Chronic Kidney Disease in People with and without Diabetes Mellitus: Secondary Analyses of Two Randomised Controlled Trials- ClinicalKey’. N.p., n.d. Web. <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300998>.
International Textbook of Diabetes Mellitus. 4th ed. John Wiley & Sons, Incorporated, 2015. Web. <http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=1895437>.
Jhamb, Shaurya, Venkat N. Vangaveti, and Usman H. Malabu. ‘Genetic and Molecular Basis of Diabetic Foot Ulcers: Clinical Review’. Journal of Tissue Viability 25.4 (2016): 229–236. Web.
Jin, Dong-mei et al. ‘Effect of Transcutaneous Electrical Nerve Stimulation on Symptomatic Diabetic Peripheral Neuropathy: A Meta-Analysis of Randomized Controlled Trials’. Diabetes Research and Clinical Practice 89.1 (2010): 10–15. Web.
Johal, S. et al. ‘Pre-Existing Diabetes Is a Risk Factor for Increased Rates of Cellular Rejection after Kidney Transplantation: An Observational Cohort Study’. Diabetic Medicine (2017): n. pag. Web.
Kaul, Sanjay. ‘Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials’. Diabetes Care 40.7 (2017): 821–831. Web.
Khunti, K. et al. ‘Clinical Inertia in People With Type 2 Diabetes: A Retrospective Cohort Study of More than 80,000 People’. Diabetes Care 36.11 (2013): 3411–3417. Web.
Khunti, Kamlesh et al. ‘Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study’. Diabetes Care 38.2 (2015): 316–322. Web.
---. ‘Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study’. Diabetes Care 38.2 (2015): 316–322. Web.
Koye, D. N. et al. ‘Incidence of Chronic Kidney Disease among People with Diabetes: A Systematic Review of Observational Studies’. Diabetic Medicine (2017): n. pag. Web.
Kunutsor, S. K., S. Seidu, and K. Khunti. ‘Aspirin for Primary Prevention of Cardiovascular and All-Cause Mortality Events in Diabetes: Updated Meta-Analysis of Randomized Controlled Trials’. Diabetic Medicine 34.3 (2017): 316–327. Web.
Liew, G., P. Mitchell, and T. Y Wong. ‘Systemic Management of Diabetic Retinopathy’. BMJ 338.feb12 1 (2009): b441–b441. Web.
Lindholm, Lars H et al. ‘Cardiovascular Morbidity and Mortality in Patients with Diabetes in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial against Atenolol’. The Lancet 359.9311 (2002): 1004–1010. Web.
‘Lipid-Lowering Efficacy of the PCSK9 Inhibitor Evolocumab (AMG 145) in Patients with Type 2 Diabetes: A Meta-Analysis of Individual Patient Data - ClinicalKey’. N.p., n.d. Web. <https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716000036>.
‘Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes’. New England Journal of Medicine 364.9 (2011): 818–828. Web.
‘Macrovascular Disease and Risk Factors in Youth with Type 1 Diabetes: Time to Be More Attentive to Treatment?- ClinicalKey’. N.p., n.d. Web. <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354>.
‘---’. N.p., n.d. Web. <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354>.
‘---’. N.p., n.d. Web. <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300354>.
Malavige, Lasantha S. et al. ‘The Association between Physical Activity and Sexual Dysfunction in Patients with Diabetes Mellitus of European and South Asian Origin: The Oxford Sexual Dysfunction Study’. European Journal of Medical Research 20.1 (2015): n. pag. Web.
Marso, Steven P. et al. ‘Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes’. New England Journal of Medicine 375.4 (2016): 311–322. Web.
Matheus, Alessandra Saldanha de Mattos et al. ‘Impact of Diabetes on Cardiovascular Disease: An Update’. International Journal of Hypertension 2013 (2013): 1–15. Web.
Mayer-Davis, Elizabeth J. et al. ‘Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002–2012’. New England Journal of Medicine 376.15 (2017): 1419–1429. Web.
Melanie Davies. ‘The Treatment of Type 2 Diabetes in the Presence of Renal Impairment: What We Should Know about Newer Therapies’. Clinical Pharmacology : Advances and Applications 8 (2016): n. pag. Web. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922775/>.
Micha, Renata et al. ‘Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States’. JAMA 317.9 (2017): n. pag. Web.
‘Microvascular Complications and Foot Care’. Diabetes Care 40.Supplement 1 (2017): S88–S98. Web.
Miller, M. E et al. ‘The Effects of Baseline Characteristics, Glycaemia Treatment Approach, and Glycated Haemoglobin Concentration on the Risk of Severe Hypoglycaemia: Post Hoc Epidemiological Analysis of the ACCORD Study’. BMJ 340.jan08 1 (2010): b5444–b5444. Web.
‘Minimizing Hypoglycemia in Diabetes: Table 1’. Diabetes Care 38.8 (2015): 1583–1591. Web.
Moreton, R. B. R. et al. ‘Factors Determining Uptake of Diabetic Retinopathy Screening in Oxfordshire’. Diabetic Medicine 34.7 (2017): 993–999. Web.
‘Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes’. New England Journal of Medicine 377.3 (2017): 300–301. Web.
Navaneethan, Sankar D. et al. ‘Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD’. American Journal of Kidney Diseases (2017): n. pag. Web.
Nicolucci, A., and E. Standl. ‘Antiplatelet Therapy for Every Diabetic Person?’ Diabetes Care 34.Supplement_2 (2011): S150–S154. Web.
‘Older Antidiabetic Drugs | The British Journal of Cardiology’. N.p., n.d. Web. <https://bjcardio.co.uk/2018/03/older-antidiabetic-drugs/>.
Omland, Torbjørn et al. ‘Relation of Erectile Dysfunction to Subclinical Myocardial Injury’. The American Journal of Cardiology 118.12 (2016): 1821–1825. Web.
Orchard, Trevor J. et al. ‘Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-Term Mortality’. JAMA 313.1 (2015): n. pag. Web.
P Naidoo. ‘Lower Limb Complications of Diabetes Mellitus: A Comprehensive Review with Clinicopathological Insights from a Dedicated High-Risk Diabetic Foot Multidisciplinary Team’. The British Journal of Radiology 88.1053 (2015): n. pag. Web. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743571/>.
Paul, Sanjoy K et al. ‘Delay in Treatment Intensification Increases the Risks of Cardiovascular Events in Patients with Type 2 Diabetes’. Cardiovascular Diabetology 14.1 (2015): n. pag. Web.
‘Personalised Blood Pressure Ranges in Type 2 Diabetes?- ClinicalKey’. N.p., n.d. Web. <https://www.clinicalkey.com/#!/content/journal/1-s2.0-S2213858718300020>.
‘---’. N.p., n.d. Web. <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858718300020>.
‘Personalised Treatment Targets in Type 2 Diabetes Patients: The Dutch Approach - ClinicalKey’. N.p., n.d. Web. <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1751991816300626>.
Pickering, Raelene J et al. ‘Recent Novel Approaches to Limit Oxidative Stress and Inflammation in Diabetic Complications’. Clinical & Translational Immunology 7.4 (2018): n. pag. Web.
Piepoli, Massimo F. et al. ‘2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice’. Atherosclerosis 252 (2016): 207–274. Web.
‘Proceedings of the 5th International DAWN Summit 2014: Acting Together to Make Person-Centred Diabetes Care a Reality - ClinicalKey’. N.p., n.d. Web. <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0168822715001862>.
Rawshani, Aidin et al. ‘Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes’. New England Journal of Medicine 376.15 (2017): 1407–1418. Web.
---. ‘Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes’. New England Journal of Medicine 376.15 (2017): 1407–1418. Web.
Ray, Kausik K et al. ‘Effect of Intensive Control of Glucose on Cardiovascular Outcomes and Death in Patients with Diabetes Mellitus: A Meta-Analysis of Randomised Controlled Trials’. The Lancet 373.9677 (2009): 1765–1772. Web.
Richard W. Nesto. ‘LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach?’ Clinical Diabetes 26.1 (2008): n. pag. Web. <http://go.galegroup.com/ps/i.do?id=GALE|A174972167&v=2.1&u=leicester&it=r&p=EAIM&sw=w&asid=07d8e79bb8f42665bb52cc5732948c88>.
Ritholz, M. D., T. MacNeil, and K. Weinger. ‘Difficult Conversations: Adults with Diabetes and the Discussion of Microvascular Complications’. Diabetic Medicine (2017): n. pag. Web.
---. ‘Difficult Conversations: Adults with Diabetes and the Discussion of Microvascular Complications’. Diabetic Medicine 34.10 (2017): 1447–1455. Web.
Romero-Aroca, Pedro et al. ‘Differences in Incidence of Diabetic Retinopathy between Type 1 and 2 Diabetes Mellitus: A Nine-Year Follow-up Study’. British Journal of Ophthalmology (2017): n. pag. Web.
---. ‘Differences in Incidence of Diabetic Retinopathy between Type 1 and 2 Diabetes Mellitus: A Nine-Year Follow-up Study’. British Journal of Ophthalmology (2017): n. pag. Web.
---. ‘Differences in Incidence of Diabetic Retinopathy between Type 1 and 2 Diabetes Mellitus: A Nine-Year Follow-up Study’. British Journal of Ophthalmology (2017): n. pag. Web.
Rosenberg, Jamie B., and Irena Tsui. ‘Screening for Diabetic Retinopathy’. New England Journal of Medicine 376.16 (2017): 1587–1588. Web.
Saha, Sandeep A., and Rohit R. Arora. ‘Fibrates in the Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus – A Pooled Meta-Analysis of Randomized Placebo-Controlled Clinical Trials’. International Journal of Cardiology 141.2 (2010): 157–166. Web.
Santi, Daniele et al. ‘Six Months of Daily Treatment with Vardenafil Improves Parameters of Endothelial Inflammation and of Hypogonadism in Male Patients with Type 2 Diabetes and Erectile Dysfunction: A Randomized, Double-Blind, Prospective Trial’. European Journal of Endocrinology 174.4 (2016): 513–522. Web.
Schrier, R. W., R. O. Estacio, and B. Jeffers. ‘Appropriate Blood Pressure Control in NIDDM (ABCD) Trial’. Diabetologia 39.12 (1996): 1646–1654. Web.
Scott, A. R. ‘Management of Hyperosmolar Hyperglycaemic State in Adults with Diabetes’. Diabetic Medicine 32.6 (2015): 714–724. Web.
Seidu, S. et al. ‘Effects of Glucose-Lowering and Multifactorial Interventions on Cardiovascular and Mortality Outcomes: A Meta-Analysis of Randomized Control Trials’. Diabetic Medicine 33.3 (2016): 280–289. Web.
Soliman, Elsayed Z. et al. ‘Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study’. Diabetes Care 40.6 (2017): 793–799. Web.
Solomon, Sharon D. et al. ‘Diabetic Retinopathy: A Position Statement by the American Diabetes Association’. Diabetes Care 40.3 (2017): 412–418. Web.
---. ‘Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418’. Diabetes Care 40.6 (2017): 809.3-809. Web.
---. ‘Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418’. Diabetes Care (2017): n. pag. Web.
---. ‘Erratum. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017;40:412–418’. Diabetes Care (2017): n. pag. Web.
Sultan, A. et al. ‘Evolution of Silent Myocardial Ischaemia Prevalence and Cardiovascular Disease Risk Factor Management in Type 2 Diabetes over a 10-Year Period: An Observational Study’. Diabetic Medicine (2017): n. pag. Web.
---. ‘Evolution of Silent Myocardial Ischaemia Prevalence and Cardiovascular Disease Risk Factor Management in Type 2 Diabetes over a 10-Year Period: An Observational Study’. Diabetic Medicine (2017): n. pag. Web.
‘The Changing Face of Diabetes Complications - ClinicalKey’. N.p., n.d. Web. <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858716300109>.
‘The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus’. New England Journal of Medicine 329.14 (1993): 977–986. Web.
‘The Evolution of Diabetic Ketoacidosis: An Update of Its Etiology, Pathogenesis and Management - ClinicalKey’. N.p., n.d. Web. <https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S0026049515003728>.
‘The Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management - NHS Health Check’. N.p., n.d. Web. <http://www.healthcheck.nhs.uk/news/the_handbook_for_vascular_risk_assessment_risk_reduction_and_risk_management/>.
Turnbull, F. M. et al. ‘Intensive Glucose Control and Macrovascular Outcomes in Type 2 Diabetes’. Diabetologia 52.11 (2009): 2288–2298. Web.
---. ‘Intensive Glucose Control and Macrovascular Outcomes in Type 2 Diabetes’. Diabetologia 52.11 (2009): 2288–2298. Web.
‘Type 1 Diabetes in Adults: Diagnosis and Management | Guidance and Guidelines | NICE’. n. pag. Web. <https://www.nice.org.uk/guidance/ng17>.
‘Type 2 Diabetes in Adults: Management | Guidance and Guidelines | NICE’. n. pag. Web. <https://www.nice.org.uk/guidance/ng28>.
UK Prospective Diabetes Study Group. ‘Tight Blood Pressure Control and Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 38’. BMJ : British Medical Journal 317.7160 (1998): n. pag. Web. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC28659/>.
Umpierrez, Guillermo, and Mary Korytkowski. ‘Diabetic Emergencies — Ketoacidosis, Hyperglycaemic Hyperosmolar State and Hypoglycaemia’. Nature Reviews Endocrinology 12.4 (2016): 222–232. Web.
---. ‘Diabetic Emergencies — Ketoacidosis, Hyperglycaemic Hyperosmolar State and Hypoglycaemia’. Nature Reviews Endocrinology 12.4 (2016): 222–232. Web.
Valencia, Willy Marcos, and Hermes Florez. ‘How to Prevent the Microvascular Complications of Type 2 Diabetes beyond Glucose Control’. BMJ (2017): n. pag. Web.
Wannamethee, S. Goya et al. ‘Impact of Diabetes on Cardiovascular Disease Risk and All-Cause Mortality in Older Men: Influence of Age at Onset, Diabetes Duration and Established and Novel Rosk Factors’. Archives of Internal Medicine 171.5 (2011): n. pag. Web.
Webb, D. R. et al. ‘Cardiovascular Risk Factors and Incident Albuminuria in Screen-Detected Type 2 Diabetes’. Diabetes/Metabolism Research and Reviews (2016): n. pag. Web.
Weber, Michael A. et al. ‘Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes’. Journal of the American College of Cardiology 56.1 (2010): 77–85. Web.
Whelton, Paul K. ‘Clinical Outcomes in Antihypertensive Treatment of Type 2 Diabetes, Impaired Fasting Glucose Concentration, and Normoglycemia’. Archives of Internal Medicine 165.12 (2005): n. pag. Web.
White, Jon et al. ‘Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes’. JAMA Cardiology 1.6 (2016): n. pag. Web.
Wong, Muh Geot et al. ‘Long-Term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON’. Diabetes Care 39.5 (2016): 694–700. Web.
---. ‘Long-Term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON’. Diabetes Care 39.5 (2016): 694–700. Web.
Yavuz, Metin et al. ‘Plantar Shear Stress in Individuals With a History of Diabetic Foot Ulcer: An Emerging Predictive Marker for Foot Ulceration’. Diabetes Care 40.2 (2017): e14–e15. Web.
Yudkin, John S, Bernd Richter, and Edwin AM Gale. ‘Intensified Glucose Control in Type 2 Diabetes—Whose Agenda?’ The Lancet 377.9773 (2011): 1220–1222. Web.
Zaccardi, Francesco, David R. Webb, Melanie J. Davies, Nafeesa N. Dhalwani, Laura J. Gray, et al. ‘Predicting Hospital Stay, Mortality and Readmission in People Admitted for Hypoglycaemia: Prognostic Models Derivation and Validation’. Diabetologia (2017): n. pag. Web.
Zaccardi, Francesco, David R. Webb, Melanie J. Davies, Nafeesa N. Dhalwani, Gemma Housley, et al. ‘Risk Factors and Outcome Differences in Hypoglycaemia-Related Hospital Admissions: A Case-Control Study in England’. Diabetes, Obesity and Metabolism (2017): n. pag. Web.
Zhang, Chun-Yu et al. ‘Effects of Intensive Glucose Control on Incidence of Cardiovascular Events in Patients with Type 2 Diabetes: A Meta-Analysis’. Annals of Medicine 42.4 (2010): 305–315. Web.
Zinman, Bernard et al. ‘Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes’. New England Journal of Medicine 373.22 (2015): 2117–2128. Web.
Zoungas, Sophia et al. ‘Effects of Intensive Glucose Control on Microvascular Outcomes in Patients with Type 2 Diabetes: A Meta-Analysis of Individual Participant Data from Randomised Controlled Trials’. The Lancet Diabetes & Endocrinology 5.6 (2017): 431–437. Web.
